This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (SDX-0101)

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2016 by SynDevRx, Inc.
Sponsor:
Information provided by (Responsible Party):
SynDevRx, Inc.
ClinicalTrials.gov Identifier:
NCT02743637
First received: April 7, 2016
Last updated: April 12, 2017
Last verified: August 2016
  Purpose
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.

Condition Intervention Phase
Advanced Malignancy Advanced Solid Tumors Neoplasm Metastasis Drug: SDX-7320 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Study of SDX-7320 to Assess the Safety and Tolerability in Patients With Advanced Refractory or Late-Stage Solid Tumors

Further study details as provided by SynDevRx, Inc.:

Primary Outcome Measures:
  • Number of participants with adverse events as a measure of safety and tolerability of SDX-7320 to find the recommended Phase II dose [ Time Frame: Up to 30 days after last subject enrolled ]

Secondary Outcome Measures:
  • Anti-tumor activity [ Time Frame: From the screening visit though the end of the last cycle on treatment, an expected average of 16 weeks ]
    RECIST v1.1


Other Outcome Measures:
  • Peak plasma concentration (Cmax) of active moiety SDX7539 [ Time Frame: Cycle 1, 3, and 6 Day 1: predose, 3, 6, 24, 48, 96 hours; Cycle 2, 4, and 5: predose ]
  • Area under the plasma concentration curve from zero to infinity AUC (0-inf) active moiety SDX7539 [ Time Frame: Cycle 1, 3, and 6 Day 1: predose, 3, 6, 24, 48, 96 hours; Cycle 2, 4, and 5: predose ]

Estimated Enrollment: 30
Actual Study Start Date: February 2016
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SDX-7320
Increasing dose cohorts, until the maximum tolerated dose (MTD) is determined.
Drug: SDX-7320
SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.

Detailed Description:

This is a Phase 1 dose escalation study to assess the safety and tolerability of subcutaneously administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.

Once the MTD has been determined up to 12 patients will be treated at this dose level, to further characterize treatment emergent adverse events (TEAEs).

  Eligibility

Ages Eligible for Study:   21 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients have at least one site of radiographically measurable disease.
  • Eastern Cooperative Oncology Group (ECOG) status ≤1.
  • Adequate renal and liver functions.
  • Life expectancy ≥3 months.

Exclusion Criteria:

  • Patients that have undergone organ transplant surgery.
  • The patient has a known history of Hepatitis A, B, or C and is on active anti-viral therapy.
  • History of gastric bypass surgery or banding procedure.
  • Uncontrolled or refractory hypertension: systolic >180 or diastolic >110, or hypotension: systolic <90 or diastolic <50 despite medical treatment.
  • Participation in any other trial of an investigational agent within 30 days prior to first dose of study drug.
  • The resting 12-lead electrocardiogram obtained during screening shows QTc (Fridericia correction) ≥470 ms or has a congenital prolonged QT syndrome.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02743637

Contacts
Contact: Neal Salomon, MD (617) 859-6508 medicalmonitor@syndevrx.com

Locations
United States, Arizona
HonorHealth Research Institute Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Joyce Schaffer    480-323-1339 ext 2    clinicaltrials@honorhealth.com   
Principal Investigator: Michael Gordon, MD         
United States, California
Cedars Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Nia Harmon    310-967-8594    Nia.Harmon@cshs.org   
Principal Investigator: Monica Mita, MD         
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact: AskSarah    615-339-4214      
Principal Investigator: Johanna Bendell, MD         
Sponsors and Collaborators
SynDevRx, Inc.
Investigators
Study Director: Neal Salomon, MD SynDevRx, Inc.
  More Information

Additional Information:
Responsible Party: SynDevRx, Inc.
ClinicalTrials.gov Identifier: NCT02743637     History of Changes
Other Study ID Numbers: SDX-0101
Study First Received: April 7, 2016
Last Updated: April 12, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by SynDevRx, Inc.:
SDX-7320
Cancer
Oncology
Solid Tumors
Phase 1
SynDevRx
MetAP2
Breast
Post menopausal
Colorectal
Pancreatic
Ovarian
Endometrial
Esophageal
Lung
Renal
Prostate
Liver

ClinicalTrials.gov processed this record on July 21, 2017